Last updated on March 2020

Durvalumab Long-Term Safety and Efficacy Study

Brief description of study

The aims of the study are to monitor the long-term safety of durvalumab, to provide continued treatment or retreatment with durvalumab to eligible patients, and to collect overall survival (OS) information.

Detailed Study Description

This is a multicenter, open-label, global study that will enroll patients who are currently receiving durvalumab monotherapy, or have previously received durvalumab as monotherapy or in combination with any other approved or investigational anticancer agents, in an eligible AstraZeneca/MedImmune-sponsored clinical study.

Clinical Study Identifier: NCT04078152

Find a site near you

Start Over

Research Site

Hirakata-shi, Japan
  Connect »